Cure8 research brief
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
This study suggests treatment use and surgery rates were similar to matched UC patients and that most IBDU patients remained unclassified over long follow-up.
Adults with a new or existing IBDU label, clinicians who diagnose and follow IBD patients, and researchers studying disease classification or long-term outcomes in IBD.
The authors used the ENEIDA registry to identify adults diagnosed with IBDU between 2010 and 2016 and matched each case with at least two UC patients by sex, age at diagnosis, and disease extent.
After a median follow-up of about 90 months, rates of immunomodulator and advanced therapy use, and rates of surgery, were similar between IBDU and matched UC patients. About 28% of IBDU patients were reclassified during follow-up (roughly half to UC and half to Crohn's disease), meaning about two-thirds remained IBDU.
Patients with baseline extensive colitis were less likely to be later reclassified as UC. How to read this This is a retrospective registry-based cohort and reports associations and reclassification patterns rather than proving causes. The summary is based on the article abstract provided by the journal.
This is a multicenter retrospective analysis from the ENEIDA registry with a median follow-up of ~90 months. As an observational registry study, findings describe patterns and associations and do not establish causal relationships.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Biogen
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
